NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
Quarterly report [Sections 13 or 15(d)]
Current report
Definitive proxy statements
View and filter by group or type
